Minicircle
plasmid gene therapy, non-viral delivery
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
plasmid gene therapy, non-viral delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Minicircle plasmid gene therapy, non-viral delivery
Minicircle describes itself as a gene therapy platform offering investigational plasmid gene therapies through independent international partner clinics. Its Follistatin therapy is presented as a non-viral, non-heritable, subcutaneous treatment intended to support lean muscle, vitality, body composition, and epigenetic age. The site also lists Klotho as coming in 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Minicircle — Translational · Bottom quartile. Derived deterministically from 10 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic